Multi-omics analysis of genetic drivers linking aortic stenosis and left ventricular diastolic dysfunction in heart failure Authors: Zeeshan Ahmed, Prithvi Govindareddy, Jayden Mathew, Naveena Yanamala, Partho P Sengupta Published: 2026 ABSTRACT AbstractBackgroundAortic stenosis (AS) and left ventricular diastolic dysfunction (LVDD) often coexist in heart failure (HF), but the mechanisms linking them remain unclear. While AS increases afterload and promotes myocardial stiffening, emerging AI-based evidence suggests LVDD can precede the development of AS or progress simultaneously, indicating shared upstream mechanobiological and inflammatory drivers. This study explores the genetic contributors connecting AS and LVDD to identify early molecular markers and convergent pathways in HF.MethodWe analyzed Whole Genome Sequence (WGS) and RNA-seq data of the HF patients, generated using their Peripheral Blood Mononuclear Cells (PBMCs) samples. Overall bioinformatics analysis was divided into two modules, 1) gene variant and annotation analysis, and 2) gene expression and enrichment analysis. We utilized our peer review published and open source WGS and RNA-seq pipelines to process Next-Generation Sequence (NGS) data. Furthermore, we performed bioinformatics and statistical analysis to identify genetic variations, expressions, regulation, enrichments, and disease annotations.ResultsWe identified genetic markers uniquely associated with AS, LVDD, and shared between them. Furthermore, we report genes with significant expression, and functional variations, and discuss their relationship with other cardiovascular diseases (e.g. Vascular and Cardiac Stiffness, Aortic Dissection, Left Atrial Enlargement, Left Ventricular Hypertrophy, Outflow Tract Obstructive Defects, Non-Compaction Coronary Artery Disease, Arrhythmia, Congestive Heart Failure, and Hypertrophic, Dilated, and Ischemic Cardiomyopathy) and non-cardiovascular diseases (non-CVDs) (e.g. Type 1 Diabetes, Diabetic Nephropathy, Skeletal Anomalies, Rheumatoid Arthritis, Atypical Femoral Fractures, Chronic Kidney Disease, Dehydrated Hereditary Stomatocytosis, Schizophrenia, Varicose Veins, High-Altitude Pulmonary Edema, Periodontitis, and Respiratory Disorder) including multiple cancer types (e.g. Breast, Lung, Colorectal, Pancreatic, Hypopharyngeal, Acute Lymphoblastic, and Oral Squamous Cell Carcinomas) and rare genetic disorders (e.g. Hypophosphatasia, Multiple Sclerosis, Campomelic Dysplasia, Lymphatic Malformation). We validated our results through state of science literature, gene-disease annotation databases, and electronic health records.ConclusionsAS and LVDD share both clinical and genomic associations, with overlapping genetic drivers that are enriched in pathways related to inflammation, extracellular matrix remodeling, and vascular stress responses. This work supports the potential of blood-based multi-omics profiling to uncover early, systemic molecular signals of cardiac dysfunction and lays the groundwork for future tissue-specific studies to guide precision diagnosis, risk stratification, and targeted therapeutics in HF.Supplementary informationThe online version contains supplementary material available at 10.1186/s13040-026-00564-y.Keywords: Aortic stenosis, Left ventricular, Diastolic dysfunction, Heart failure, Genetic markers Introduction Heart Failure (HF) is among the most significant causes of morbidity and mortality around the globe [1, 2]. Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all HF cases and has traditionally been attributed to myocardial stiffness and impaired diastolic relaxation [3]. Aortic stenosis (AS), long viewed as a valvular disease that causes left ventricular (LV) dysfunction through pressure overload, is now increasingly recognized as being present even in early HFpEF. Large registries, such as the ESC Heart Failure Long-Term Registry, report that approximately 10% of HF patients have aortic valve disease, with AS particularly prevalent in the HFpEF subgroup [4]. Clinical studies further show that mild AS and aortic sclerosis often coexist with subclinical left ventricular diastolic dysfunction (LVDD), suggesting an early and underappreciated connection between these conditions [5]. Furthermore, patients with AS, even after transcatheter valve replacement, show ongoing myocardial stiffening, inflammation, and extracellular-matrix expansion, which influences progression of HFpEF [6]. Recent advances in AI-based predictive models have further challenged the conventional downstream model of AS-induced dysfunction; deep learning algorithms trained on echocardiography and ECG data demonstrate that diastolic dysfunction scores can predict future AS progression, even in patients with anatomically normal valves [7–10]. These findings support the idea that diastolic dysfunction may have a shared pathophysiology with AS. To explain this paradox, we hypothesize that AS and LVDD arise in parallel from a common mechanoinflammatory environment marked by arterial stiffness, elevated afterload, and disrupted ventriculo–valvular–vascular coupling. This shared biomechanical and inflammatory dynamics provides a unifying framework for understanding the co-evolution of AS and LVDD, particularly in HFpEF. Despite growing clinical and experimental evidence supporting this model, the underlying genetic architecture that may drive this interconnected pathology remains poorly understood. Evidence from the Framingham Heart Study suggests that cardiovascular disease (CVD) has a complex multifactorial etiology including a genetic component [11]. Multi-omics data, including high-quality sequenced DNA and RNA of transcribed genes, can inform us of a HF patient’s inherent genetic makeup with the most comprehensive view of the genome [12]. DNA-based gene variant detection, when combined with RNA-seq-driven gene expression analysis has the potential to reveal novel genetic markers and stratify HF patient populations based on their disease risk [13, 14]. We conducted a multi-omics investigation using whole genome sequencing (WGS) and RNA sequencing (RNA-seq) of peripheral blood mononuclear cells (PBMCs) from HF patients. This approach allowed us to interrogate both inherited genetic variants and active transcriptional changes, offering a broad view of systemic pathways relevant to cardiac remodeling. PBMCs, although peripheral, reflect immune and inflammatory activity, which plays a central role in both myocardial and valvular pathology. Our analysis integrated variant annotation, gene expression profiling, enrichment analysis, and disease annotation to identify distinct and overlapping genetic signatures associated with AS and LVDD. These findings provide new insight into the molecular mechanisms linking valvular and myocardial dysfunction and support the development of precision diagnostics and targeted therapies for patients at risk of HFpEF. Methodology In this study, we analyzed Whole Genome Sequence (WGS, n = 96) and RNA-seq (n = 61, with matched WGS samples) data of the HF and Cardiomyopathy patients, generated using their PBMCs samples. We utilized Illumina NovaSeq6000 S4 (2×150bp) for sequencing with 30X coverage using Illumina compatible library (e.g., Nextera DNA Flex; TruSeq Stranded mRNA). The WGS cohort was based on 35 female and 60 male cases aged between 29 to 94 years, and one unknown case. However, RNA-seq cohort included 21 female and 40 male cases aged between 45 to 92 years. Further details about gender, age, ethnicity, and sequence data are provided in the Supplementary Material #1. The RNA-seq dataset was compared against healthy control samples (n = 11) without any reported HF diagnosis. Informed consent was obtained from all subjects. All human samples were used in accordance with relevant guidelines and regulations, and all experimental protocols were approved by the Institutional Review Board (IRB) at Rutgers University. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institution and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. We utilized our peer review published, and open source WGS and RNA-seq pipelines to process Next-Generation Sequence (NGS) data. Furthermore, we performed downstream bioinformatics and statistical analysis to identify target genetic variations, expressions, regulations, enrichments, pathways, and disease annotations. Overall data analysis was divided into two modules, 1) gene variant and annotation, and 2) gene expression and enrichment. Gene variant and annotation We processed WGS data (n = 96) using JWES [15], which mainly applies Burrows–Wheeler Aligner (BWA) for mapping sequence data against the reference human genome (hg38) [16], and Genome Analysis Toolkit (GATK) for variant discovery and annotation [17]. The outcome of JWES is a Variant Call Format (VCF) file, which we utilized for further downstream analysis, including variant-level quality filtering, classification of coding variations, and identification of functionally relevant alleles associated with AS, LVDD, and both [18]. We utilized Ensembl Variant Effect Predictor (VEP) to predict the effect of variants [19], calculated functional prediction scores using database of Single Nucleotide Polymorphisms (dbSNP) [20], drawn gene-variant-disease relationship with ClinVar [21], and interpreted variant using population allele frequencies from genome Aggregation Database (gnomAD) [22]. We performed functional variant burden analysis and based on the alterations predicted to produce substantial disruption in protein structure and function, we categorized variants into three main categories i.e., high, moderate, and low impact. Variant impact categories were defined in accordance with the Ensembl Variant Effect Predictor (VEP) consequence classification framework [19]. High impact variants comprise predicted loss-of-function alterations, including stop-gained, frameshift, splice acceptor, and splice donor variants, expected to cause substantial disruption of protein structure and function. Moderate impact variants encompass missense substitutions and in-frame insertions or deletions predicted to alter protein properties without complete abrogation of function. Low impact variants include synonymous substitutions and other changes unlikely to affect protein function. Modifier variants represent intronic, intergenic, and other non-coding alterations with uncertain or minimal functional consequences. The term “functional variants” throughout this study refers to variants predicted to produce biologically relevant alterations in gene or protein function, encompassing high and moderate impact variants as classified by VEP, as well as protein-altering variants further supported by pathogenicity prediction scores from SIFT [20] and PolyPhen-2, both integrated within the dbNSFP annotation database [20], and cross-referenced against ClinVar disease-variant associations [21]. The descriptor “highly pathogenic” applied to specific BIRC5 and MYBPC3 variants reflects ClinVar pathogenicity classifications [21], while “highly damaging” applied to the ITGB1 variant reflects combined SIFT and PolyPhen-2 deleteriousness scores, both standard frameworks in clinical genomics variant interpretation. Furthermore, we utilized annotation databases including Gene Ontology (GO) [23], Kyoto Encyclopedia of Genes and Genomes (KEGG) [24], Reactome Knowledgebase (RK) [25], and Human Phenotype Ontology (HPO) [26] to identify and validate pathogenic variants with potential biological relevance to AS, LVDD, and both. We visualized results, most importantly by generating network diagrams annotating gene-variant and gene-variant-disease relationships. Gene expression and enrichment We processed RNA-seq data (n = 61) using GVViZ pipeline [27], which mainly applies HISAT (hierarchical indexing for spliced alignment of transcripts) [28] with Bowtie2 [29] to align the sequences against reference hg38, and RSEM (RNA by Expectation Maximization) for the quantification and identification of differentially expressed genes (DEGs) by aligning reads to reference de novo transcriptome assemblies [30]. The major outcome of this pipeline includes quality metrics, isoforms, and gene expressions. Next, we extracted and classified genes relevant to AS, LVDD and both, based on their expression values to perform gene expression, enrichment and annotation analysis. We performed pathway and disease enrichment analysis to identify biological processes and molecular interaction networks overrepresented within the stratified gene sets. Functional enrichment was conducted using the KEGG database to associate cellular functions with stratified gene sets. The enrichment analysis included calculation of False Discovery Rate (FDR) cutoff of 0.05 to control Type I errors and maintain rigorous multiple-testing corrections. DEGs were identified based on these FDR values and an absolute log2 fold change threshold of >1.5 and were then utilized for pathway and disease enrichment analysis. Enrichment was restricted to pathways with a minimum of two and a maximum of 5,000 genes to eliminate overly broad or narrow biological categories, ensuring results remained relevant to cardiovascular physiology, and redundant terms and overlapping ontologies were filtered to provide a concise, non-redundant functional summary of the biological findings. The top twenty significantly enriched pathways from each dataset were identified and projected to visualize gene enrichment signatures. These visualizations characterized the enrichment ratio, gene count, and statistical significance, highlighting the primary molecular mechanisms and biological themes associated with each HF phenotype. Results We identified through extensive literature review and cross-referencing with established disease–gene and pathway databases, nine genes known to be associated with AS (BMP2, TGFB3, ALPL, ITGA5, RUNX2, SPP1, PIEZO1, AREG, SOX9), nine genes reported for their role in LVDD (MYBPC3, COL3A1, TGFB2, SOD2, BIRC5, ANKRD1, MYH9, NDRG1, GDF15), and twenty seven genes shared between both AS and LVDD (TGFB1, NOS3, IL6, AGT, AGTR1, MPO, NOTCH1, ACE, COL1A1, LGALS3, MMP9, TIMP1, TNF, TNNI3, TNNT2, RHOA, ITGB1, PTK2, FN1, ROCK1, FOXO1, CRP, MMP2, AMOTL2, NPPB, YAP1, TTN). The gene selection was based on prior experimental and clinical evidence of disease association, including differential expression, functional involvement in key pathophysiological processes (e.g., calcification, fibrosis, inflammation, and myocardial remodelling), and support from curated resources such as DisGeNET [31], and pathway/ontology annotations including GO [23], KEGG [24], and Reactome [25]. Functional characterization further suggested that these genes were also enriched in biological processes central to cardiovascular disease, including extracellular matrix organization, inflammatory signalling, and cardiac muscle contraction, supporting their relevance to AS and LVDD. Further, we report genes with significant expression regulation, functional variations, and their relationship with AS, LVDD, and other CVDs and non-CVDs including multiple cancer types and rare genetic disorders (Tables 1 and 2). Table 1Gene, expression, variants associated with aortic stenosis (AS), left ventricular diastolic dysfunction (LVDD), and shared between AS and LVDD, and other cardiovascular diseases (CVDs)CategoryGeneExpressionVariantOtherCardiovascular DiseaseACMGAortic Stenosis (AS)BMP2Lowrs235768, rs2273073Congenital Heart DiseaseNot listedrs2273073Ventricular Septal Defect 1Not listedTGFB3LowN/AN/ANot listedALPLHighN/AN/ANot listedITGA5HighN/AN/ANot listedRUNX2Lowrs147359883, rs11498198Aortic Valve CalcificationNot listedrs2480999044, rs138287579Valve StiffnessNot listedSPP1Lowrs11728697, rs4660Coronary Artery Disease, AtherosclerosisNot listedPIEZO1Highrs34830861Venous Vascular DiseaseNot listedrs114034093CardiomyopathyNot listedAREGLowrs28364979, rs62314511Post-Myocardial Infarction RemodelingNot listedSOX9LowN/AN/ANot listedLeft Ventricular Diastolic Dysfunction(LVDD)MYBPC3Lowrs767039057, rs397515937, rs34580776, rs3729989, rs727503173, rs187705120, rs730880694, rs121909374, rs3729952, rs35078470Hypertrophic CardiomyopathyACMG Approvedrs3729986Hypertrophic Cardiomyopathy, Left Ventricular Non-Compactionrs397516075Hypertrophic Cardiomyopathy, Dilated Cardiomyopathyrs200352299Hypertrophic Cardiomyopathy, Left Ventricular Non-Compactionrs730880565Cardiomyopathyrs35078470ArrhythmiaCOL3A1Lowrs35795890, rs41263773Vascular Ehlers–Danlos SyndromeACMG Approvedrs111840783Cervical Artery DissectionTGFB2LowN/AN/ANot listedSOD2N/Ars8073069Ischemic CardiomyopathyNot listedrs4880Dilated CardiomyopathyNot listedBIRC5Lowrs17878467Myocardial RemodelingNot listedrs9904341Ischemic CardiomyopathyNot listedrs35550482Dilated Cardiomyopathy, Hypertrophic CardiomyopathyNot listedANKRD1Lowrs397517249, rs28730751Dilated Cardiomyopathy, Hypertrophic CardiomyopathyNot listedrs2233340Cardiac Hypertrophy, Heart FailureNot listedMYH9HighN/AN/ANot listedNDRG1Highrs776351924,rs36076004, rs2233322Cardiac Hypertrophy, Heart FailureNot listedGDF15Lowchr19:g.18386214 G > C, chr19:g.18386331T > A, chr19:g.18388595 G > T, chr19:g.18388612C > GCoronary Artery DiseaseNot listedShared genes between AS and LVDDTGFB1Highrs1800470Ischemic Heart DiseaseNot listedrs1800472Coronary Heart DiseaseNot listedNOS3Lowrs1799983, rs3918166, rs7792133, rs3918201Coronary Artery Disease, Ischemic StrokeNot listedIL6Lowrs2069830Ischemic StrokeNot listedAGTLowrs699Coronary Artery Disease, HypertensionNot listedrs4762Left Ventricular Hypertrophy, HypertensionNot listedrs1805090, chr1:g.230710814C > GHypertensionNot listedAGTR1Lowrs1800766HypertensionNot listedMPOLowrs35897051Coronary Artery DiseaseNot listedNOTCH1Lowrs9411208, rs138504021Bicuspid AortopathyNot listedrs61751543, rs61751489Left Ventricular Outflow Tract Obstructive Defects, Aortic DissectionNot listedrs3125001, rs61751542Bicuspid Aortic Valve, AneurysmNot listedrs1842916834, rs111309246, rs61733294, rs2229968, rs367710569, rs183156491, rs149057410, rs2229970, rs1843256337, rs187473846Adams-Oliver Syndrome 5Not listedACELowrs56394458, rs12709426Cardioembolic StrokeNot listedrs4363Myocardial InfarctionNot listedrs4330, rs4976, rs28730839, rs4303, rs12720730HypertensionNot listedCOL1A1Lowrs1800215Postoperative Atrial Fibrillation and Myocardial IschemiaNot listedLGALS3Highchr14:g.55138318A > CCoronary Artery DiseaseNot listedMMP9Highrs3918242Ischemic StrokeNot listedrs1805088, rs8125581Abdominal Aortic AneurysmNot listedTIMP1HighchrX:g.47585341C > T, chrX:g.47585480 G > C, chrX:g.47585524 G > A, chrX:g.47586579C > THypertensionNot listedTNFLowN/AN/ANot listedTNNI3Lowchr19:g.55156279C > A, chr19:g.55157141A > TDilated CardiomyopathyACMG ApprovedTNNT2Lowchr1:g.201359139 G > A, chr1:g.201359144C > T, chr1:g.201361214C > T, chr1:g.201361257C > T, chr1:g.201361301T > C, chr1:g.201361940A > G, chr1:g.201365603C > T, chr1:g.201369853T > C, chr1:g.201372097C > T, chr1:g.201377210 G > AIdiopathic Dilated CardiomyopathyACMG ApprovedRHOAHighrs2878298, rs11716445Vascular StiffnessNot listedITGB1Highrs1456697974, rs2488325, rs45580338, rs1187075Cardiac Remodeling, Cardiac StiffnessNot listedPTK2Lowrs768652102, rs79812711, rs191376716Vascular Calcification, Cardiac Fibrosis, Vascular RemodelingNot listedFN1Lowrs1250229, rs1250259Coronary Artery DiseaseNot listedROCK1Lowrs2663698, rs201390233, rs748791602, rs113763420, rs2510624972Atherosclerosis, Vascular StiffnessNot listedFOXO1Lowrs963605898, rs34733279Coronary Artery Disease, Pathological Cardiac HypertrophyNot listedCRPLowrs77832441Coronary Artery DiseaseNot listedMMP2LowN/AN/ANot listedAMOTL2LowN/AN/ANot listedNPPBLowN/AN/ANot listedYAP1Lowrs112417656, rs61746398Myocardial InfractionNot listedTTNLowrs72646898Arrhythmogenic Right Ventricular CardiomyopathyACMG Approvedrs202094100Arrhythmogenic Syndromesrs922984, rs3731746Atrial Fibrillationrs79926414Cardiomyopathyrs922985Congestive Heart Failurers3829746, rs2042995, rs2627043, rs199506676, rs72648980, rs199565715, rs4894028, rs72646840, rs56308529, rs16866465, rs16866391Dilated Cardiomyopathyrs140909116Fetal Cardiomyopathyrs140319117Hereditary Myopathyrs200103997, rs190636272, rs72648989, rs72648958, rs371366196, rs180975448Hypertrophic Cardiomyopathyrs9808377Left Atrial Enlargementrs10497520Left Ventricular Hypertrophyrs7585334, rs744426, rs2303838, rs16866406, rs2288569, rs1001238, rs13390491, rs12693166Long-QT Syndromers72648937, rs72648927, rs146181116Dilated Cardiomyopathy 1 G, Heart Failurers33971253Cardiomyopathyrs72650064Supraventricular Tachycardia cardiomyopathyrs886055288, rs146983095, rs201474544, rs201158906, rs201797790, rs72646809, rs543102139, rs374741129, rs199997460, rs142973956, chr2:g.178597612T > A, rs55675869, rs72648257, rs56145100, rs189030321, rs3731745, rs56018860, rs3813246, rs3813245, rs2288570, rs2303832, rs2562847, rs2742347, rs1883085, rs2562829, rs66677602, rs2306636, rs56142888, rs12476289, rs36043230, rs62621236, rs59148238, rs747122, rs10164753, rs115658240, rs568086259, rs73973133, rs73973139, rs138787974, rs73973147, rs16866531, rs56201325, rs202032281, chr2:g.178748553A > G, rs16866378, rs3731752, rs2278196, rs72629779, rs56027402, rs56057221, rs56309296, rs56365600, rs55861600, rs3813243, rs16866412, rs762149243, rs72650032, rs72650028, rs4893852, rs13398235, rs28626194, rs16866477, rs16866489, rs72648915, rs75785339, rs72648903, rs57389274, rs55980498, rs72648982, rs72647876, rs187925021, rs34618570, rs151253841, chr2:g.178559745C > T, rs762932429, rs141973925, rs11888217, rs4893853, rs4894048, rs72648270, rs201512527, rs116676813, chr2:g.178532720A > G, rs774191975, rs377571654, rs372710684, rs765307374, rs72646869, rs146313925, rs17355446, rs66961115, rs67254537, rs56324595, rs33917087, rs185683410, rs570608843, rs16866457, rs750853901, rs766753906, rs374022393, rs200317412, chr2:g.178749888C > G, rs149001703, rs72648206, chr2:g.178537165 G > A, rs752768925, rs72648970, rs55742743, rs72648969, chr2:g.178543541C > A, chr2:g.178784076T > G, rs1336768417, chr2:g.178756286 G > C, rs375577529, rs201541213, rs200355367, rs199796249, rs72648949, rs55842557, rs36021856, chr2:g.178710845A > G, chr2:g.178541293A > G, rs72648946, rs115532048, rs72647875, rs201674674, chr2:g.178575058T > G, chr2:g.178620867A > G, rs376820301, rs373636988, rs138846756, rs200648462, chr2:g.178574667T > G, rs72648942, rs67665715, rs11887722, rs11896637, rs744427, rs72646881, rs62618736, rs371943746, rs77960621, rs73038324, rs16866475, rs72648984, rs72648930, rs199561793, rs72648221, rs767038885, rs201257644, chr2:g.178537750C > T, rs200819643, rs201918596, rs55948748, chr2:g.178615713A > G, chr2:g.178730966T > A, chr2:g.178534656 G > A, rs1490243211, chr2:g.178568743C > G, rs12471771, rs68080670, rs727505311, rs200840285, chr2:g.178740277 G > T, rs202011992, rs72648256, rs72648925, rs750610895, chr2:g.178747804 G > T, rs149748934, rs55866005, chr2:g.178573425T > A, rs149660690, chr2:g.178573254T > C, rs770499179, rs751929345, chr2:g.178677836 G > T, chr2:g.178729003A > T, rs779238709, rs202032875, rs55886356, chr2:g.178604167T > C, rs201043950, rs146970027, rs55704830, rs369566893Dilated Cardiomyopathy 1 G, Early-onset myopathy with fatal cardiomyopathy Gene, expression, variants associated with aortic stenosis (AS), left ventricular diastolic dysfunction (LVDD), and shared between AS and LVDD, and other cardiovascular diseases (CVDs) Left Ventricular Diastolic Dysfunction (LVDD) rs776351924, rs36076004, rs2233322 Table 2Gene, expression, variants associated with aortic stenosis (AS), left ventricular diastolic dysfunction (LVDD), and shared between AS and LVDD, and non-cardiovascular diseases (non-CVDs)CategoryGeneExpressionVariantNon-Cardiovascular DiseaseACMGAortic stenosis (AS)BMP2Lowrs235768Short Stature, Facial Dysmorphis, Skeletal AnomaliesNot listedrs2273073Ossification of the Posterior Longitudinal LigamentNot listedTGFB3Lowrs761225134Loeys-Dietz Syndrome 5Not listedALPLHighrs149344982, rs121918007, rs3200254, rs201739155, rs34605986, rs1397418141, rs139811782HypophosphatasiaNot listedrs74063111Atypical Femoral FracturesNot listedITGA5Lowrs73322228Rheumatoid ArthritisNot listedrs150458044Multiple SclerosisNot listedrs112896207Type 1 Diabetes MellitusNot listedRUNX2LowN/AN/ANot listedSPP1Lowrs138638879Chronic Kidney DiseaseNot listedrs7435825Early-Onset Inflammatory Bowel Disease, Systemic Lupus ErythematosusNot listedPIEZO1Lowrs144035770Chronic Kidney DiseaseNot listedrs201019404PIEZO1-related conditionNot listedrs35544968Ankylosing SpondylitisNot listedrs1803382, rs35159887, rs34370460, rs139051768, rs11645197, rs202103485, rs13333358, rs6500493, rs115486714, rs6500495Dehydrated Hereditary StomatocytosisNot listedrs2290901Hemolytic Disease of the Fetus and NewbornNot listedrs13338527, rs200970763Lymphatic Malformation 6Not listedrs188337046SchizophreniaNot listedrs565096713Varicose VeinsNot listedrs35265318OtosclerosisNot listedrs7184427Varicose Veins, Lymphatic Malformation 6Not listedAREGLowN/AN/ANot listedSOX9Lowrs1224146749Varicose VeinsNot listedrs375577899SOX9-related conditionNot listedrs191619615Campomelic DysplasiaNot listedLeft Ventricular Diastolic Dysfunction(LVDD)COL3A1Lowrs762269632Vascular Ehlers–Danlos SyndromeACMG Approvedrs1800255Pelvic Organ Prolapsers1516446Adamantinomatous CraniopharyngiomasTGFB2Lowrs10482810Pancreatic CancerNot listedrs10482721Loeys–Dietz Syndrome Type 4Not listedSOD2Lowrs4880Breast CancerNot listedchr6:g.159692858C > AType 1 DiabetesNot listedrs5746099Diabetic Nephropathy, Breast CancerNot listedBIRC5Lowrs17880183, rs17885521Lung CancerNot listedANKRD1LowN/AN/ANot listedMYH9Highrs140588099, rs578002660, rs2269529, rs150029980, rs56200894MYH9-related disorderNot listedNDRG1Lowrs2233319Charcot-Marie-Tooth Disease Type 4DNot listedrs887167637Lung CancerNot listedGDF15LowN/AN/ANot listedShared genes between AS and LVDDTGFB1Highrs1800471, rs11466358Type 1 Diabetes MellitusNot listedNOS3Lowrs3918201, rs3918232, rs3918234, rs149539813High-Altitude Pulmonary EdemaNot listedrs79467411Restless Legs SyndromeNot listedrs143125350Willis-Ekbom DiseaseNot listedIL6Lowrs13306435Sciatic Pain and Lumbar Disc DiseaseNot listedrs2069842PeriodontitisNot listedAGTLowrs61731497Renal Tubular DysgenesisNot listedAGTR1Lowrs12721317Type 1 DiabetesNot listedrs34561787Myelin Oligodendrocyte Glycoprotein-Associated DiseaseNot listedMPOLowrs2071409Hypertensive Disorders of PregnancyNot listedrs55929952Prostate CancerNot listedrs7208693, rs2759Acute Kidney InjuryNot listedchr17:58278036 G > AMyeloperoxidase DeficiencyNot listedrs56378716Recurrent Fungal InfectionsNot listedNOTCH1Lowrs79782048Alzheimer’s DiseaseNot listedACELowrs56394458Alzheimer’s Disease, Intracerebral HemorrhageNot listedrs12709426, rs4330, rs4976, rs28730839, rs4364, rs148995315Alzheimer’s DiseaseNot listedrs3730025Renal Tubular Dysgenesis, Lung CancerNot listedrs117647476, rs4363, rs147429960, rs4298, rs114861086Renal Tubular Dysgenesis of genetic originNot listedCOL1A1Lowrs1800215Combined Osteogenesis Imperfecta, Ehlers-Danlos SyndromeNot listedrs66592376Classical Ehlers-Danlos SyndromeNot listedrs72667032Ehlers-Danlos Syndrome, Osteogenesis Imperfecta, Connective tissue disordersNot listedrs41316657, rs41317361, rs41316667Ehlers-Danlos Syndrome, Osteogenesis ImperfectaNot listedrs375914028Ehlers-Danlos Syndrome, Osteogenesis Imperfecta, COL1A1-related disordersNot listedrs201682029, rs767250343Osteogenesis ImperfectaNot listedLGALS3Highchr14:g.55138217C > A, chr14:g.55142700 G > ABreast and Colorectal CancerNot listedchr14:g.55138318A > CType 2 Diabetes, Rheumatoid ArthritisNot listedrs10148371Breast NeoplasmsNot listedMMP9Lowrs41427445, rs28763886, rs17576, hrX:g.47585341C > T, chr20:g.46014472 G > AMetaphyseal Anadysplasia 2Not listedrs3918256Pelvic Organ ProlapseNot listedTIMP1HighchrX:g.47585341C > TNeuromyelitis Optica spectrum disordersNot listedTNFLowrs4645843Polycystic Ovary SyndromeNot listedTNNI3LowN/AN/AACMG ApprovedTNNT2LowN/AN/AACMG ApprovedRHOAHighN/AN/ANot listedITGB1LowN/AN/ANot listedPTK2LowN/AN/ANot listedFN1Lowrs1250209, rs2577301, rs2577301Spondylometaphyseal DysplasiaNot listedrs17449032, rs767081660, rs55822567Glomerulopathy with Fibronectin DepositsNot listedrs139078629, rs147831535, rs140926439Chronic Kidney DiseaseNot listedROCK1LowN/AN/ANot listedFOXO1LowN/AN/ANot listedCRPLowrs1800947Prostate CancerNot listedMMP2LowN/AN/ANot listedAMOTL2Lowrs2124982421Myelin Oligodendrocyte glycoprotein antibody-associated DiseaseNot listedNPPBLowrs759741420Type 1 DiabetesNot listedYAP1Lowrs2033082Crohn’s DiseaseNot listedTTNLowrs3829747, rs6723526, rs72648998, rs35813871Acute Lymphoblastic LeukemiaACMG Approvedrs3731749Oral Squamous Cell Carcinomars34924609Respiratory Disorderrs13021201, rs55880440Desmoplastic Small Round Cell Tumorrs72677233Diabetic Kidney Diseasers2288563, rs2562832Hepatocellular Carcinomars34819099Multiple Sclerosisrs202014478, rs72677231, rs72650031, rs72677225, rs17452588, rs17354992Age-related Macular Degenerationrs2163008Primary Open-angle Glaucomars2627037, rs2291310, rs2291311Parkinson’s Diseasers12463674, rs2244492Breast Cancerrs4145333, rs36051007Muscular Dystrophyrs139504522Central serous chorioretinopathyrs72648244Cutaneous Melanomars35683768Hypopharyngeal Cancerrs200021871Non-Gestational Choriocarcinomars1552280, rs56308529, rs16866465, rs72647851, rs16866538, rs201263441Muscular Dystrophyrs12693164, rs2562830, rs34070843, rs72647877, rs72648907, rs55801134Myofibrillar Myopathyrs755415340Tibial Muscular Dystrophy, Myofibrillar Myopathyrs144587343, rs886055288,rs146983095, rs201474544,rs201158906, rs201797790, rs72646809, rs543102139,rs374741129, rs199997460,rs142973956, chr2:g.178597612T > A, rs55675869, rs72648257, rs56145100, rs189030321, rs3731745, rs56018860, rs3813246, rs3813245, rs2288570, rs2303832, rs2562847, rs2742347, rs1883085, rs2562829, rs66677602, rs2306636, rs56142888, rs12476289, rs36043230, rs62621236, rs59148238, rs747122, rs10164753, rs115658240, rs568086259, rs73973133, rs73973139, rs138787974, rs73973147, rs16866531, rs56201325, rs202032281, chr2:g.178748553A > G, rs16866378, rs3731752, rs2278196, rs72629779, rs56027402, rs56057221, rs56309296, rs56365600, rs55861600, rs3813243, rs16866412, rs762149243, rs72650032, rs72650028, rs4893852, rs13398235, rs28626194, rs16866477, rs16866489, rs72648915, rs75785339, rs72648903, rs57389274, rs55980498, rs72648982, rs72647876, rs187925021, rs34618570, rs151253841, chr2:g.178559745C > T, rs762932429,rs141973925, rs11888217, rs4893853, rs4894048, rs72648270, rs201512527,rs116676813, chr2:g.178532720A > G, rs774191975,rs377571654, rs372710684,rs765307374, rs72646869, rs146313925, rs17355446, rs66961115, rs67254537, rs56324595, rs33917087, rs185683410, rs570608843, rs16866457, rs750853901,rs766753906, rs374022393,rs200317412, chr2:g.178749888C > G, rs149001703, rs72648206, chr2:g.178537165 G > A, rs752768925, rs72648970, rs55742743, rs72648969, chr2:g.178543541C > A, chr2:g.178784076T > G, rs1336768417, chr2:g.178756286 G > C, rs375577529,rs201541213, rs200355367,rs199796249, rs72648949, rs55842557, rs36021856,chr2:g.178710845A > G,chr2:g.178541293A > G, rs72648946, rs115532048, rs72647875, rs201674674, chr2:g.178575058T > G, chr2:g.178620867A > G, rs376820301,rs373636988, rs138846756,rs200648462, chr2:g.178574667T > G, rs72648942, rs67665715, rs11887722, rs11896637, rs744427, rs72646881, rs62618736, rs371943746, rs77960621, rs73038324, rs16866475, rs72648984, rs72648930, rs199561793, rs72648221, rs767038885, rs201257644, chr2:g.178537750C > T, rs200819643, rs201918596, rs55948748, chr2:g.178615713A > G, chr2:g.178730966T > A, chr2:g.178534656 G > A, rs1490243211, chr2:g.178568743C > G, rs12471771, rs68080670, rs727505311, rs200840285, chr2:g.178740277 G > T, rs202011992, rs72648256, rs72648925, rs750610895, chr2:g.178747804 G > T, rs149748934, rs55866005, chr2:g.178573425T > A, rs149660690, chr2:g.178573254T > C, rs770499179, rs751929345, chr2:g.178677836 G > T, chr2:g.178729003A > T, rs779238709, rs202032875, rs55886356, chr2:g.178604167T > C, rs201043950, rs146970027, rs55704830, rs369566893Autosomal recessive limb-girdle Muscular Dystrophy type 2J Gene, expression, variants associated with aortic stenosis (AS), left ventricular diastolic dysfunction (LVDD), and shared between AS and LVDD, and non-cardiovascular diseases (non-CVDs) Left Ventricular Diastolic Dysfunction (LVDD) Gene variant profiling and annotation The WGS data analysis, uncovered functional variants from genes associated with AS, LVDD, and may have convergent role in AS and LVDD. Furthermore, we investigated their relationships with other CVDs. To characterize the WGS dataset, we performed a comprehensive descriptive variant analysis across all 96 samples. A total of 3,469,545 to 4,400,530 single nucleotide variants (SNVs) were identified per sample, with a mean of 3,632,878 SNVs in male samples (n = 60) and 3,655,876 SNVs in female samples (n = 35). Across the 45 target genes associated with AS, LVDD, and their shared biology, a total of 16,136 unique variant-gene pairs were identified. Functional annotation of target gene variants revealed that the majority were classified as modifier impact (mean 2,713 per sample, ~93%), reflecting intronic and non-coding alterations, followed by low impact variants (mean 75 per sample, ~2.6%), predominantly synonymous substitutions. Moderate impact variants, including missense substitutions, were identified at a mean of 46 per sample (~1.6%), while high impact variants, comprising predicted loss-of-function alterations such as stop-gained and splice-disrupting changes, were identified in a subset of samples (7 of 96 samples, mean 0.1 per sample). Across the cohort, the most frequently observed variant consequences in target genes included intronic variants (n = 205,084), downstream gene variants (n = 25,735), upstream gene variants (n = 20,212), synonymous variants (n = 4,906), and missense variants (n = 4,313), with three stop-gained variants identified across the cohort. Comparison of variant profiles between male and female samples revealed no statistically significant differences in SNV counts (Mann-Whitney U = 964.0, p = 0.507), moderate impact variants (U = 948.5, p = 0.434), or high impact variants (U = 1022.5, p = 0.832) within target genes, suggesting that the genomic landscape of AS- and LVDD-associated loci is broadly consistent across sexes. At the genome-wide level, a marginal but statistically significant difference in total SNV burden was observed between male (mean = 3,632,878) and female (mean = 3,655,876) samples (U = 695.0, p = 0.006), though the biological significance of this difference is likely limited given the small effect size. Variant frequency analysis within the target gene cohort identified 6,534 singleton variants (observed in a single sample), 3,231 low-frequency variants (cohort allele frequency 0.01–0.05), 3,848 common variants (AF 0.05–0.50), and 2,523 high-frequency variants (AF > 0.50). Cross-referencing with gnomAD genome frequencies revealed that the majority of variants in target genes are classified as common in the general population (gnomADg AF > 0.05, n = 46,404), while 2,888 variants were ultra-rare (gnomADg AF < 0.001) and 1,047 were rare (gnomADg AF 0.001–0.01), highlighting a subset of potentially disease-relevant low-frequency alleles. Recurrence analysis identified variants present across a very high proportion of samples (≥20 samples) in genes including TTN, ALPL, AGT, and TNNT2, consistent with common population-level polymorphisms in these large and highly variable genes. In contrast, disease-relevant variants with moderate recurrence (present in 5–19 samples) were identified across multiple AS- and LVDD-associated genes including MYBPC3, NOTCH1, ACE, and ROCK1, reflecting a combination of population-enriched and potentially disease-contributing alleles. AS associated gene-variant profiling CVD associations for AS-related genes were obtained through gene-variant-disease network analysis (Fig. 1A). Variant profiling disclosed variants for five AS genes (Fig. 2A, Table 1). Only two moderate impact variants were identified each for AREG, PIEZO1, and SPP1 with one high impact variant for SPP1. BMP2 and RUNX2, however, had three and four moderate variants identified respectively. Associations between these five genes and CVDs were limited. BMP2 showed three functional variants (rs235768, rs2273073, rs2273073), observed across eighty-four participants, associated with congenital heart disease-related phenotypes, including ventricular septal defects. AREG exhibited two functional variants (rs28364979, rs62314511) in seventy-two participants, which were related to post-myocardial infarction remodeling. PIEZO1 displayed two functional variants in eighty-four participants linked to venous vascular disease (rs34830861) and cardiomyopathy (rs114034093). SPP1 exhibited two protein-altering variants (rs11728697, rs4660) in sixty-six participants, strongly impactful for coronary artery disease and atherosclerosis. RUNX2 showed four functional variants in fifty-four participants, associated with aortic valve calcification (rs147359883, rs11498198) and valve stiffness (rs2480999044, rs138287579). Gene-variant and expression analysis. (A) Gene-variant network of genes associated with aortic stenosis (AS), left ventricular diastolic dysfunction (LVDD), and shared between AS and LVDD. (B) Expression analysis of genes associated with AS, LVDD, and shared between LVDD and AS Variant, expression and enrichment analysis of targeted genes. (A) Variants, expression and enrichment analysis of targeted genes associated with aortic stenosis (AS). (B) Variants, expression and enrichment analysis of targeted genes associated with left ventricular diastolic dysfunction (LVDD). (C) Variants, expression and enrichment analysis of targeted genes shared between AS and LVDD LVDD associated gene-variant profiling CVD associations for LVDD-related genes were derived from gene-variant-disease network analysis (Fig. 1A). Variant profiling disclosed variants for seven LVDD genes (Fig. 2B, Table 1). Fifteen variants were identified for MYBPC3 with two high impact variants. Three moderate variants were identified for COL3A1, BIRC5, ANKRD1, and NDRG1 with one BIRC5 variant as highly pathogenic. Four moderate variants were found for GDF15 and two for SOD2. Among the curated LVDD-associated genes, MYBPC3 showed fifteen distinct variants in forty-eight participants. These variants were found to be associated with cardiomyopathy-related phenotypes, including two protein-altering variants being highly pathogenic for hypertrophic cardiomyopathy (rs767039057, rs397515937, rs34580776, rs3729989, rs727503173, rs187705120, rs730880694, rs121909374, rs3729952, rs35078470, rs3729986, rs397516075, rs200352299), dilated cardiomyopathy (rs397516075, rs730880565), left ventricular non-compaction (rs3729986, rs200352299), and Arrhythmia (rs35078470). COL3A1 displayed three functional variants across all participants, linked to Vascular Ehlers–Danlos Syndrome (rs35795890, rs41263773) and Cervical Artery Dissection (rs111840783). SOD2 harbored two functional variants in seventy-three participants, associations included ischemic cardiomyopathy (rs8073069) and dilated cardiomyopathy (rs4880). GDF15 exhibited four functional variants (chr19:g.18386214 G > C, chr19:g.18386331T > A, chr19:g.18388595 G > T, chr19:g.18388612C > G) in eighty-five participants, related to coronary artery disease. BIRC5 showed three functional variants in seventy-five participants, and its CVD associations included one high impact protein altering variant for myocardial remodeling (rs17878467), ischemic cardiomyopathy (rs9904341), dilated cardiomyopathy, and hypertrophic cardiomyopathy (rs35550482). ANKRD1 showed three functional variants in sixty-three participants, connected to dilated cardiomyopathy and hypertrophic cardiomyopathy (rs397517249, rs28730751), and cardiac hypertrophy and HF (rs2233340). NDRG1 showed three functional variants in eighty-one participants, reported for cardiac hypertrophy and HF (rs776351924, rs36076004, rs2233322). Gene-variant profiling of genes shared between AS and LVDD We identified twenty-seven genes with shared biology in AS and LVDD (Figs. 1A, and 2A and B). However, variant profiling disclosed variants for twenty-four genes associated with other CVDs (Fig. 2C, and Table 1). These genes include TGFB1, NOS3, IL6, AGT, AGTR1, MPO, NOTCH1, ACE, COL1A1, LGALS3, MMP9, TIMP1, TNF, TNNI3, TNNT2, RHOA, ITGB1, PTK2, FN1, ROCK1, FOXO1, CRP, YAP1, TTN. We found two functional variants in TGFB1 across seventy-three participants, which were associated with ischemic heart disease (rs1800470) and coronary heart disease (rs1800472). NOS3 showed four functional variants (rs1799983, rs3918166, rs7792133, rs3918201) across fifty-seven participants and linked to coronary artery disease and ischemic stroke. AGT displayed four functional variants within seventy-four participants, related to coronary artery disease and hypertension (rs699), left ventricular hypertrophy (rs4762) and hypertension (rs1805090, chr1:g.230710814C > G). NOTCH1 showed sixteen functional variants observed in eighty-eight participants, related to bicuspid aortopathy (rs9411208, rs138504021), left ventricular outflow tract obstructive defects, aortic dissection (rs61751543, rs61751489), bicuspid aortic valve, aneurysm (rs3125001, rs61751542), and Adams-Oliver syndrome 5 (rs1842916834, rs111309246, rs61733294, rs2229968, rs367710569, rs183156491, rs149057410, rs2229970, rs1843256337, rs187473846). ACE revealed eight functional variants in ninety-six participants with one high impact variant associated with hypertension (rs4330, rs4976, rs28730839, rs4303, rs12720730), cardioembolic stroke (rs56394458, rs12709426), and myocardial infarction (rs4363). MMP9 expressed three functional variants identified in ninety-six participants, linked with ischemic stroke (rs3918242) and abdominal aortic aneurysm (rs1805088, rs8125581). TIMP1 showed four functional variants observed in fifty-four participants, associated with hypertension (chrX:g.47585341C > T, chrX:g.47585480 G > C, chrX:g.47585524 G > A, chrX:g.47586579C > T). TNNT2 expressed ten functional variants (chr1:g.201359139 G > A, chr1:g.201359144C > T, chr1:g.201361214C > T, chr1:g.201361257C > T, chr1:g.201361301T > C, chr1:g.201361940A > G, chr1:g.201365603C > T, chr1:g.201369853T > C, chr1:g.201372097C > T, chr1:g.201377210 G > A) within twenty-four participants, which were linked to idiopathic dilated cardiomyopathy. ITGB1 showed four functional variants (rs1456697974, rs2488325, rs45580338, rs1187075) identified in seventy-one participants, with one highly damaging variant linked to cardiac remodeling and cardiac stiffness. PTK2 expressed three functional variants (rs768652102, rs79812711, rs191376716) detected in forty-eight participants, associated with vascular calcification, cardiac fibrosis, and vascular remodeling. ROCK1 showed five functional variants (rs2663698, rs201390233, rs748791602, rs113763420, rs2510624972) observed in fifty-seven participants, with one high impact variant associated with atherosclerosis and vascular stiffness. Few genes reported just two functional variants associated with similar CVDs, which include TNNI3 (chr19:g.55156279C > A and chr19:g.55157141A > T; dilated cardiomyopathy) identified in forty-four participants, RHOA (rs2878298 and rs11716445; vascular stiffness) observed in sixty-two participants, FN1 (rs1250229 and rs1250259; coronary artery disease) present in eighty-six participants, FOXO1 (rs963605898 and rs34733279; coronary artery disease and pathological cardiac hypertrophy) identified in sixty-nine participants, and YAP1 (rs112417656 and rs61746398; myocardial infraction) observed in fifty-two participants with one high impact variant. In addition to these, a single CVD related functional variant was exhibited by the following genes; IL6 (rs2069830l; ischemic stroke) observed across sixty-five participants, a high impact variant for AGTR1 (rs1800766; hypertension) within twenty-seven participants and MPO (rs35897051l coronary artery disease) within fifty-one participants, COL1A1 (rs1800215; postoperative atrial fibrillation and myocardial ischemia) detected in fifteen participants, LGALS3 (chr14:g.55138318A > C; coronary artery disease), and CRP (rs77832441; coronary artery disease) detected in fourteen participants. We identified most of the functional variants (n = 276, Table 1) in TTN among ninety-one participants, which were associated with variable AS, LVDD, and many other CVDs including arrhythmogenic right ventricular cardiomyopathy, arrhythmogenic syndromes, atrial fibrillation, cardiomyopathy, congestive HF, dilated cardiomyopathy, fetal cardiomyopathy, hereditary myopathy, hypertrophic cardiomyopathy, left atrial enlargement, left ventricular hypertrophy, long-QT syndrome, dilated cardiomyopathy 1 G, HF, cardiomyopathy, supraventricular tachycardia cardiomyopathy, and, early-onset myopathy with fatal cardiomyopathy. Detailed classification is provided in Table 1 (Fig. 3A and B). Gene-disease network. (A) Gene-variant-disease network of genes associated with aortic stenosis (AS), left ventricular diastolic dysfunction (LVDD), and shared between AS and LVDD. (B) Gene-variant-disease network of genes associated with other cardiovascular diseases (CVDs). (C) Gene-variant-disease network of genes associated with non-cardiovascular diseases (non-CVDs) We have verified, validated and interpreted reported genes using American College of Medical Genetics and Genomics (ACMG) criteria [32, 33]. We found MYBPC3, COL3A1, TNNI3, TNNT2, and TTN among ACMG approved list of genes and contain pathogenic variants relevant to AS, LVDD and other CVDs and non-CVDs (Tables 1 and 2). Gene expression and enrichment Integrating In-house developed and published bioinformatics pipelines with systematic expression stratification and pathway enrichment, we ensured the precise identification of transcriptionally active genes that drive the biological convergence between AS and LVDD phenotypes leading to HF. Transcriptomic profiling across the case group (IDs 1058–1118) and the control group (IDs 648–659) was performed in two steps. First, gene expression analysis of all genes known to be associated with AS, LVDD, and have a strong overlapping between both AS and LVDD (Figs. 1B, and 2A, B, and C). This was conducted to identify specific upregulation or downregulation patterns, especially regarding significant DEGs that were identified using quantified expression values. Second, gene enrichment analysis of all genes known to be associated with AS, LVDD, and strongly intersect between AS and LVDD (Fig. 2A, B, and C). AS-associated gene expression analysis AS-specific gene expression identified heatmap-based expression for all nine markers with major association to vascular mineralization and cardiac remodeling (Fig. 2A). Differential expression analysis identified ALPL, ITGA5, and PIEZO1 as significant DEGs (FDR < 0.05, log2 fold change > 1.5), exhibiting a distinct variating downregulation pattern in the case cohort compared to controls (Fig. 2A). ALPL was the highly expressed gene in this subset, with significantly high intensity in the control group. Gene expression profiling showed variable intensity in ALPL expression in case samples (Fig. 2A). CVD found coronary calcification [34] and mineralization-related disorders [35]. ITGA5 also exhibited a high-intensity profile that was very strong in the control group in comparison to specific elderly case subjects. Expression analysis indicated high ITGA5 expression across the control group (Fig. 2A). CVD associations involved cell-matrix adhesion [36] and structural remodeling [37]. Similarly, PIEZO1 displayed high intensity in controls and a slightly lower distribution in case subjects (Fig. 2A). CVD links are limited to mechanotransduction [38, 39] and pressure regulation [40, 41]. RUNX2 showed a lower expression in controls, which was absent across most of the case group with some subjects having little or no expression at all. This marker has a crucial role in vascular calcification [42], fibrosis, and arterial stiffness [43] causing inflammation linked to matrix remodeling in CVD progression [44]. The remaining AS markers, SPP1 and TGFβ3 did not show any significant variation in expression as it was too low to compare while BMP2, SOX9, and AREG had no expression across the comparison groups. The expression profiling and highest fold enrichment analysis of AS genes revealed Hippo, PI3K-AKT, and TGF-β as statistically significant signaling pathways which play a vital role in the interconnected networks controlling cell growth, survival, and proliferation of cardiomyocytes, differentiation, and inflammation. Crosstalk of these pathways regulates heart development and repair, while their dysregulation contributes to HF, hypertrophy, and vascular disease, making them key therapeutic targets. LVDD-associated gene expression analysis LVDD-specific gene expression identified heatmap-based expression for eight markers with major characterized by dominant structural and stress-response markers (Fig. 2B). Differential expression analysis identified MYH9 and NDRG1 as significant DEGs (FDR < 0.05, log2 fold change > 1.5), characterized by a marked downregulation in the case cohort compared to the healthy control baseline (Fig. 2B). MYBPC3 and BIRC5 showed a moderately lower expression. MYH9 expressed solid high intensity in control subjects, while expression was significantly variable in case group (Fig. 2B). CVD associations include hypertension [45] and cardiac remodeling [46]. NDRG1 also exhibited consistently high intensity in the control group, while showing considerably variable and lower intensity in the case group (Fig. 2B). Its CVD associations involve cellular stress [47] response in myocardial tissues. MYBPC3 showed moderately low expression in controls in comparison to LVDD cases where the expression dropped further (Fig. 2B). CVD associations include HF and hypertrophic cardiomyopathy [48]. BIRC5 also displayed faintly low expression in the case cohort, slightly more visible in the control group (Fig. 2B). It is known to be involved in cell survival signaling in HF [49]. Very low expression was observed in TGFB2, GDF15, COL3A1, and ANKRD across both groups (Fig. 2B). These genes are associated with syndromic aortic aneurysm, metabolic survival proteins, and cardiac ankyrin repeat protein activity [50–53]. The expression profiling and highest fold enrichment analysis of LVDD genes revealed Hippo signaling, the AGE-RAGE pathway and cytoskeletal dynamics as the statistically significant pathways. The AGE-RAGE signaling significantly contributes to cardiomyopathy and CVD triggering inflammation, and damaging cytoskeletal integrity, particularly altering actin can lead to cell damage, fibrosis, hypertrophy, and impaired heart function. This disrupts cardiomyocyte structure and function with cytoskeletal changes playing a crucial role in cellular stiffness and contractility, promoting conditions like HF. Gene-expression analysis of genes shared between AS and LVDD The gene expression analysis of the subset of genes shared between LVDD and AS reflected interrelated role and shared molecular biology functions in the diseases (Fig. 2C). Based on the established criteria (FDR < 0.05, log2 fold change > 1.5), TGFB1, TIMP1, and RHOA were identified as significant downregulated DEGs in the case cohort compared to controls (Fig. 2C). They are critically involved in cardiovascular fibrosis and remodeling [54–57]. MMP9 and ITGB1 also showed considerably high expression with distinctly lower expression in the case group. They are primarily involved in extracellular matrix (ECM) remodeling, inflammation, and cellular migration [58–61]. NOTCH1, ROCK1, and FOXO1 had low expressions in the case group while little or no expression was observed in the control group. They are linked to chronic hypoxic cardiomyocyte conditions [62–64]. LGALS3 showed consistently high in both cases and control group. Although it is a robust and active biomarker of chronic inflammation and HF regardless of the specific phenotype it did not any considerable variation between the comparison groups. MPO, TNF, ACE, NOS3, and FAK showed insignificant expression across the comparison groups. Statistical analysis revealed AGE-RAGE, cardiomyopathy, stress in atherosclerosis, and TGFB signaling as significant with respect to shared genes. The AGE–RAGE axis plays a key role in cardiovascular disease by promoting oxidative stress, inflammation, and endothelial dysfunction, thereby accelerating atherosclerosis and myocardial injury. In cardiomyopathy, chronic metabolic and inflammatory stress activates dysfunctional signaling pathways that impair cardiac structure and function. Cellular stress responses, including oxidative and mechanical stress, further contribute to vascular inflammation and plaque progression in atherosclerosis. Additionally, dysregulated TGF-β signaling is central to cardiac remodeling and fibrosis, influencing vascular stiffness, myocardial hypertrophy, and disease progression across multiple forms of CVD. To examine the relationship between genomic variation and transcriptional dysregulation, we performed an integrative analysis of WGS variant burden and RNA-seq expression findings within the curated 45 target gene set. Differential expression analysis identified eight significant DEGs across the three gene groups, including ALPL, ITGA5, and PIEZO1 for AS; MYH9 and NDRG1 for LVDD; and TGFB1, TIMP1, and RHOA for shared genes, all meeting the threshold of FDR < 0.05 and absolute log2 fold change greater than 1.5, and all exhibiting downregulation in the case cohort relative to controls. Variant burden analysis within these eight DEGs revealed a mean of 447 variant observations per gene across the 96-sample WGS cohort, compared to a mean of 339 per gene among the remaining 37 non-DEG target genes, representing a 32% higher variant burden in transcriptionally dysregulated genes. Notably, PIEZO1, MYH9, and ALPL showed the highest combined variant and expression burden, suggesting that accumulated genomic variation in these loci may contribute to their transcriptional dysregulation in HF. It is important to note that this integrative analysis was conducted within the scope of the curated target gene set, as the RNA-seq analysis in this study was focused on these disease-relevant genes. Broader transcriptome-wide integration of WGS variant enrichment with genome-wide differential expression profiles represents an important direction for future investigation and would further strengthen the multi-omics framework proposed in this study. Discussion Molecular drivers of AS mineralization Expression profiling of AS genes identified Hippo, PI3K–AKT, and TGF-β signaling as significantly enriched pathways [65], highlighting their roles in regulating cardiomyocyte growth, survival, differentiation, and inflammation. Crosstalk among these pathways governs cardiac development and repair, while their dysregulation promotes hypertrophy, vascular disease, and HF. Enrichment of these genes was dominated by mechanotransduction and structural remodeling, including Hippo signaling, PI3K–Akt signaling, ECM–receptor interaction, and focal adhesion, underscoring the role of mechanical stress in valvular and early cardiac remodeling. Reduced expression of cell–matrix adhesion and mechanosensory genes in cases suggests impaired cellular responses to pressure overload and progressive disruption of the valvular interstitium. AS progression reflects a transition of valvular cells toward an osteoblast-like phenotype [66]. The low expression of AS genes likely drives the pro-calcific microenvironment and accelerates valvular stiffening as mechanical signaling becomes increasingly dysregulated [67]. Genomic landscape of LVDD pathogenesis LVDD genes showed enrichment in Hippo signaling, AGE–RAGE signaling, and cytoskeletal dynamics as dominant pathways [68]. AGE–RAGE activation contributes to inflammation, oxidative stress, and cytoskeletal damage, promoting fibrosis, hypertrophy, and impaired myocardial relaxation [69]. Alterations in actin and sarcomeric components directly affect cardiomyocyte stiffness and contractility, central features of diastolic dysfunction [70]. LVDD-specific genes showed the highest enrichment in cytoskeletal components with significant overrepresentation of hypertrophic, dilated, and diabetic cardiomyopathy pathways, reinforcing the role of structural and metabolic stress [71]. The reduced expression of these genes in cases indicates loss of transcriptional stability in pathways essential for myocardial integrity and mechanical load management. Downregulation of key regulators of contraction and relaxation likely impairs calcium sensitivity, contributing to delayed relaxation and disease progression. Shared molecular frameworks for myocardial and valvular remodeling Shared gene analysis revealed significant enrichment of AGE–RAGE signaling, cardiomyopathy pathways, stress-related atherosclerosis mechanisms, and TGF-β signaling, defining a common molecular response to chronic pressure overload. The AGE–RAGE axis promotes inflammation, oxidative stress, endothelial dysfunction, and matrix remodeling. It alters the actin cytoskeleton modifying the structural integrity of the heart muscles. While dysregulated TGF-β signaling drives fibrosis, myocardial hypertrophy, and tissue stiffening across cardiovascular phenotypes. Gene enrichment further highlighted hypertrophic cardiomyopathy, TGF-β signaling, and the renin–angiotensin system, linking systemic stressors such as hypertension to local myocardial and valvular remodeling. Cardiac remodeling potentially is directed by how the heart adapts its structure to maintain function under different types of stress. High-expression functional analysis emphasized actin cytoskeleton regulation, leukocyte transendothelial migration, and proteoglycan-related pathways, reflecting active structural reorganization and inflammatory signaling. Across both AS and LVDD, shared genes converge on inflammation and extracellular matrix (ECM) turnover as core drivers of disease. While ECM-regulatory genes showed stable expression in controls, their heterogeneous and reduced expression in cases suggests a dysregulated “fibrotic flux,” marked by imbalance between matrix synthesis and degradation. Collectively, these findings indicate that AS and LVDD are linked by a unified transcriptomic program of chronic inflammation, impaired mechanosensing, and maladaptive tissue remodeling rather than representing isolated disease processes. Biomarkers with strong associations reported for AS have also been linked to multiple non-CVDs. These include chronic disorders such as rheumatoid arthritis [72], multiple sclerosis [73], type 1 diabetes mellitus [74], chronic kidney disease [75], early-onset inflammatory bowel disease [76], systemic lupus erythematosus [77], ankylosing spondylitis [78], schizophrenia [79], ossification of the posterior longitudinal ligament, and atypical femoral fractures [80]. Several rare diseases have also been associated with these genes, including skeletal anomalies [81] (congenital/genetic forms), Loeys–Dietz syndrome type 5, hypophosphatasia, lymphatic malformation 6, and campomelic dysplasia. Many non-CVD conditions were found to be associated with the targeted genes. For LVDD-associated genes, linked non-CVD conditions include chronic diseases such as type 1 diabetes mellitus [82], diabetic nephropathy [83], and pelvic organ prolapse; rare diseases including vascular Ehlers–Danlos syndrome [84], Loeys–Dietz syndrome type 4 [85], MYH9-related disorder, and Charcot–Marie–Tooth disease type 4D; as well as several cancers, including lung cancer [86], breast cancer [87], pancreatic cancer [88], and adamantinomatous craniopharyngioma [89]. Genes shared between AS and LVDD have also been linked to multiple chronic diseases, cancers, and rare diseases [90]. Detailed classification is provided in Table 2 (Fig. 3A and C). In the gene expression analysis, the distribution of age at the time of HF diagnosis across genders indicated a slighter earlier diagnosis in males (45 years and older) compared with females (51 years and older). Similarly, age distribution based on variant profiling revealed an earlier onset of the disease in males (29 years and older) than in females (51 years and older). Molecular biomarkers of a shared mechanoinflammatory mechanism in AS and LVDD The molecular findings from this study provide direct evidence linking specific identified biomarkers to the central hypothesis that AS and LVDD co-evolve from a shared mechanoinflammatory environment characterized by arterial stiffness, elevated afterload, and disrupted ventriculo–valvular–vascular coupling. Among the 27 shared genes, TGFB1, RHOA, and ROCK1 most directly reflect the mechanosensory and fibrotic components of such a framework. TGFB1 was among the most highly expressed genes in control subjects, with considerably lower expression observed in HF cases, and with two functional variants (rs1800470, rs1800472) associated with ischemic heart disease and coronary heart disease respectively, consistent with the dysregulated TGF-β signaling identified here as a potential driver of fibrosis, myocardial hypertrophy, and tissue stiffening. RHOA similarly showed very high expression in controls with considerably lower expression in cases, and its two functional variants (rs2878298, rs11716445) associated with vascular stiffness, supporting its role within the vascular stiffness component of the shared disease environment. ROCK1 on the other hand showed low expression in cases with little or no expression in controls and had a high-impact functional variant associated with atherosclerosis and vascular stiffness, further reflecting the pressure-mediated cytoskeletal remodeling that is enriched in the shared pathway analysis. The ECM remodeling signature identified among the shared genes between AS and LVDD provides additional molecular grounding for the disrupted ventriculo–valvular–vascular coupling component of the hypothesis. MMP9 and ITGB1 showed considerably high expression in controls with distinctly lower expression in cases, while TIMP1 showed very high expression in controls with considerably lower expression in HF cases. Together, these expression profiles reflect the dysregulated “fibrotic flux” described in this study, characterized by an imbalance between matrix synthesis and degradation. Functional variants in MMP9 (rs3918242, rs1805088, rs8125581) were linked to ischemic stroke and abdominal aortic aneurysm, TIMP1 variants (chrX:g.47585341C > T, chrX:g.47585480 G > C, chrX:g.47585524 G > A, chrX:g.47586579C > T) were associated with hypertension, and ITGB1 carried a highly damaging variant linked to cardiac remodeling and cardiac stiffness, consistent with the pressure overload and vascular stiffness mechanisms described in the central hypothesis. The inflammatory component of the mechanoinflammatory hypothesis is also supported by several shared genes. NOTCH1, which had the highest diversity of functional variants in this study, was associated with bicuspid aortopathy, aortic dissection, and left ventricular outflow tract defects, supporting its role in ventriculo–valvular structural regulation. IL6, TNF, CRP, and MPO collectively define an inflammatory gene signature linking systemic immune activation to both valvular calcification and myocardial fibrosis (Table 1). LGALS3 showed consistently high expression across both case and control groups with no considerable variation between them, consistent with its characterization in this study as a robust biomarker of chronic inflammation and HF irrespective of specific phenotype, suggesting it reflects a constitutively active rather than disease-stage-specific inflammatory signal. TTN, which had the largest number of functional variants (n = 276, across 91 participants), was associated with a broad spectrum of cardiovascular phenotypes—including cardiomyopathies, arrhythmias, and ventricular hypertrophy—supporting its role as a sarcomeric stress-response integrator linking valvular and myocardial dysfunction. Finally, the pathway enrichment findings across all three gene subsets provide the strongest transcriptomic support for the shared upstream regulation proposed in the central hypothesis. Hippo signaling was significantly enriched in both the AS-specific and LVDD-specific gene sets. AGE–RAGE signaling was significantly enriched in both the LVDD-specific and shared gene sets. TGF-β signaling was significantly enriched in both the AS-specific and shared gene sets. The co-enrichment of these pathways across both AS and LVDD gene sets, rather than their segregation into disease-specific signatures, is consistent with the hypothesis that the two conditions share common upstream mechanobiological and inflammatory drivers, and represents the most direct pathway-level evidence from this study supporting the proposed parallel co-evolution model of AS and LVDD in HF. Conclusion To investigate the genetic basis of the interconnected pathology of AS and LVDD, we performed a multi-omics blood-based analysis of HF patients. Integration of genetic variants and transcriptional profiles with pathway and disease enrichment analyses revealed distinct and overlapping molecular signatures associated with AS and LVDD. Notably, the rate of shared genetic markers was higher than that observed for AS- or LVDD-specific markers, supporting a strong biological relationship between the two conditions. Importantly, the biomarkers directly supporting the mechanoinflammatory co-evolution hypothesis—including TGFB1, ROCK1, and RHOA (mechanosensory-fibrotic axis); MMP9, TIMP1, COL1A1, and ITGB1 (ECM remodeling and vascular coupling disruption); NOTCH1 (ventriculo–valvular structural coupling); IL6, TNF, CRP, MPO, and LGALS3 (chronic inflammatory milieu); and TTN (sarcomeric stress response integrator)—collectively define a shared upstream molecular program of impaired mechanosensing, chronic inflammation, and dysregulated ECM remodeling. The convergent enrichment of AGE–RAGE, TGF-β, and Hippo signaling pathways across both AS- and LVDD-associated gene sets further confirms that these conditions share a common mechanobiological regulatory program rather than representing sequentially or causally linked isolated disease processes. These findings, across age and gender, validated through state-of-the-science literature, gene–disease annotation databases, and electronic health records, highlight the power of blood-based multi-omics profiling to capture early detection markers linking valvular and myocardial dysfunction. As a minimally invasive and clinically scalable approach, peripheral blood analysis provides an important foundation for the development of precision diagnostics and targeted therapies for patients at risk of HFpEF. While tissue-specific next-generation sequencing, may further refine cell-level mechanisms, blood-based genomic signatures offer a practical and translational framework for early risk stratification and personalized disease management. Limitations of our study include, no further experiments were performed to further validate our results (e.g., sequencing to confirm WGS variants, RT-qPCR to verify RNA-seq expression patterns). Furthermore, we had limited access to the clinical records, but available details are provided in the Supplementary Materials. In the future, we recommend utilizing heart tissue sequencing along with PBMCs for more direct sequencing and localized information on the molecular state of cardiomyocytes and structural remodeling. In addition, it could be valuable to test associations that link individual variants to AS/LVDD and other CVD status. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements This research was conducted with the great support of Division of Cardiovascular Diseases and Hypertension, Department of Medicine, Robert Wood Johnson Medical School (RWJMS), and Rutgers Institute for Health, Health Care Policy, and Aging Research (IFH), Rutgers Health, NJ. We express sincere gratitude to the current and former members of Ahmed Lab at Rutgers RWJMS/IFH, and appreciate all colleagues, collaborators and institutions who provided direct and indirect insight and expertise that greatly assisted the research and development of this project. We acknowledge the Office of Advanced Research Computing (OARC) at Rutgers University for providing access to the Amarel cluster and associated research computing resources that have contributed to the development and testing of this application. Reported research in this publication was supported by Rutgers University, through Rutgers Health Center for Biomedical Informatics & Health Artificial Intelligence (BMIHAI) Pilot Grant Program to Z.A. The content is solely the responsibility of the authors and does not necessarily represent the official views of the institutions. Abbreviations Aortic Stenosis Burrows–Wheeler Aligner Cardiovascular disease Database of Single Nucleotide Polymorphisms Differentially Expressed Genes Extracellular Matrix False Discovery Rate Genome Analysis Toolkit Genome Aggregation Database Gene Ontology Heart Failure Heart failure with preserved ejection fraction Human Phenotype Ontology Human Henome 38 Left Ventricular Left Ventricular Diastolic Dysfunction Institutional Review Board Kyoto Encyclopedia of Genes and Genomes Non-cardiovascular disease Next-generation sequence Peripheral blood mononuclear cells Reactome Knowledgebase RNA by Expectation Maximization RNA Sequencing Variant Call Format Variant Effect Predictor Whole genome sequence Author contributions Z.A. led this study; participated in patient consenting, sample collection, and management; generated WGS and RNA-seq data; implemented genomic pipelines to process sequence data; computed gene expressions and discovered variants. P.G. performed bioinformatics analysis to extract, annotate, and visualize target variants. J.M. performed bioinformatics analysis to analyze gene expression and enrichment, and visualized results in heatmaps and bubble plots. N.Y. and P.S. proposed and guided this study and provided strong collaborative support. Z.A. drafted and edited manuscript and figures, and all authors participated in writing, reviewed and approved this study for publication. Funding No funding was received. Data availability Available on request. Declarations Ethical approval and consent to participate Informed consent was obtained from all subjects. All human samples were used in accordance with relevant guidelines and regulations, and all experimental protocols were approved by the Institutional Review Board (IRB) at UConn Health and Rutgers University. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institution and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Consent for publication Not applicable. Biographical note Z.A. is an Assistant Professor at the Department of Medicine, Division of Cardiovascular Diseases and Hypertension, Robert Wood Johnson Medical School (RWJMS), and a Core Faculty Member at the Rutgers Institute for Health, Health Care Policy, and Aging Research (IFH), Rutgers Health. Furthermore, ZA is the Adjunct Assistant Professor at the School of Medicine, UConn Health, CT. P.G. and J.M. are Research Assistant at the Ahmed lab, Rutgers IFH/RWJMS. N.Y. is an Associate Professor of Medicine, Section Chief of Clinical Research & AI Innovation, and Director of Data Science and Machine Learning Research in the Division of Cardiology at Rutgers Robert Wood Johnson Medical School in New Brunswick, NJ. Additionally, she directs the Center for Innovation at RWJUH, serves as an Editorial Board Member for the American Society of Echocardiography (ASE), and holds roles as Associate Editor for Translational Systems Biology and In Silico Trials. P.S. is the Henry Rutgers Professor of Cardiology and the Chief of the Division of Cardiovascular Diseases & Hypertension at Rutgers Robert Wood Johnson Medical School and the Chief of Cardiac Services at the Robert Wood Johnson University Hospital. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement Available on request.